AU2022417615A1 - Therapeutic treatment for fragile x-associated disorder - Google Patents

Therapeutic treatment for fragile x-associated disorder Download PDF

Info

Publication number
AU2022417615A1
AU2022417615A1 AU2022417615A AU2022417615A AU2022417615A1 AU 2022417615 A1 AU2022417615 A1 AU 2022417615A1 AU 2022417615 A AU2022417615 A AU 2022417615A AU 2022417615 A AU2022417615 A AU 2022417615A AU 2022417615 A1 AU2022417615 A1 AU 2022417615A1
Authority
AU
Australia
Prior art keywords
fmri
seq
aso
polynucleotide
rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022417615A
Other languages
English (en)
Inventor
Joel D. Richter
Sneha Shah
Jonathan Watts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Massachusetts Amherst
Original Assignee
University of Massachusetts Amherst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Massachusetts Amherst filed Critical University of Massachusetts Amherst
Publication of AU2022417615A1 publication Critical patent/AU2022417615A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3525—MOE, methoxyethoxy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022417615A 2021-12-23 2022-12-23 Therapeutic treatment for fragile x-associated disorder Pending AU2022417615A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163265989P 2021-12-23 2021-12-23
US63/265,989 2021-12-23
PCT/US2022/082380 WO2023122800A1 (en) 2021-12-23 2022-12-23 Therapeutic treatment for fragile x-associated disorder

Publications (1)

Publication Number Publication Date
AU2022417615A1 true AU2022417615A1 (en) 2024-06-27

Family

ID=85199427

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022417615A Pending AU2022417615A1 (en) 2021-12-23 2022-12-23 Therapeutic treatment for fragile x-associated disorder

Country Status (9)

Country Link
EP (1) EP4453212A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025501755A (cg-RX-API-DMAC10.html)
KR (1) KR20240133725A (cg-RX-API-DMAC10.html)
CN (1) CN118679257A (cg-RX-API-DMAC10.html)
AU (1) AU2022417615A1 (cg-RX-API-DMAC10.html)
CA (1) CA3240593A1 (cg-RX-API-DMAC10.html)
IL (1) IL313726A (cg-RX-API-DMAC10.html)
MX (1) MX2024007908A (cg-RX-API-DMAC10.html)
WO (1) WO2023122800A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025240947A1 (en) * 2024-05-17 2025-11-20 University Of Massachusetts Therapeutic treatment for fragile x-associated disorder

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5039660A (en) 1988-03-02 1991-08-13 Endocon, Inc. Partially fused peptide pellet
WO1998010090A1 (en) 1996-09-06 1998-03-12 St. Elizabeth's Medical Center Of Boston, Inc. Gata-6 transcription factor: compositions and methods
ES2756326T3 (es) * 2010-07-19 2020-04-27 Ionis Pharmaceuticals Inc Modulación de la expresión de distrofia miotónica-proteína quinasa (DMPK)
WO2012174610A1 (en) * 2011-06-24 2012-12-27 Murdoch Childrens Research Institute Treatment and diagnosis of epigenetic disorders and conditions
ES2728782T3 (es) 2012-05-25 2019-10-28 Univ California Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
EP4397759A3 (en) 2012-10-23 2024-10-09 Toolgen Incorporated Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof
PT2931898E (pt) 2012-12-12 2016-06-16 Harvard College Manipulação e otimização de sistemas, métodos e composições para manipulação de sequências com domínios funcionais
KR102955556B1 (ko) 2012-12-12 2026-04-22 더 브로드 인스티튜트, 인코퍼레이티드 서열 조작을 위한 crispr-cas 성분 시스템, 방법 및 조성물
WO2014093694A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
MX380562B (es) 2012-12-12 2025-03-12 Broad Inst Inc Modificaciones de sistemas, métodos y composiciones guía optimizadas para la manipulación de secuencias.
CN105209621B (zh) 2012-12-12 2021-05-25 布罗德研究所有限公司 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
CA2921457A1 (en) * 2013-08-16 2015-02-19 Rana Therapeutics, Inc. Heterochromatin forming non-coding rnas
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
WO2018170290A1 (en) * 2017-03-15 2018-09-20 Fulcrum Therapeutics, Inc. Compositions and methods for increasing fmr1 expression
GB2574243A (en) * 2018-05-31 2019-12-04 The Govening Council Of The Univ Of Toronto Adeno-associated viral vector-mediated gene therapy for treating fragile X-associated disorders
MX2021010255A (es) * 2019-02-26 2021-12-15 Nogra Pharma Ltd Oligonucleotidos que interferen con proteina de retraso mental de x fragil y metodos para usar los mismos.
EP3966326A1 (en) * 2019-05-07 2022-03-16 Ecole Polytechnique Federale De Lausanne (Epfl) Fmrp and cancer treatment
CN113151406B (zh) * 2021-03-25 2022-06-21 深圳会众生物技术有限公司 Fmr1基因cgg重复数及甲基化检测试剂盒和检测方法

Also Published As

Publication number Publication date
JP2025501755A (ja) 2025-01-23
WO2023122800A1 (en) 2023-06-29
KR20240133725A (ko) 2024-09-04
CN118679257A (zh) 2024-09-20
CA3240593A1 (en) 2023-06-29
MX2024007908A (es) 2024-09-10
EP4453212A1 (en) 2024-10-30
IL313726A (en) 2024-08-01

Similar Documents

Publication Publication Date Title
US20260007766A1 (en) Compositions and methods of treating muscle atrophy and myotonic dystrophy
AU2024202093A1 (en) Peptides and nanoparticles for intracellular delivery of mrna
CA3099522C (en) GAPMERES AND METHODS OF USING THESE FOR THE TREATMENT OF MUSCULAR DYSTROPHY
JP2025526712A (ja) オリゴヌクレオチド組成物及びその方法
EP3394259B1 (en) Compositions and methods for decreasing tau expression
US20180312839A1 (en) Methods and compositions for increasing smn expression
KR20170029512A (ko) 인트론 잔류의 감소
EP4603589A2 (en) Micellar nanoparticles and uses thereof
EP3272868A1 (en) Organic compositions to treat kras-related diseases
US8344127B2 (en) Organic compositions to treat beta-ENaC-related diseases
JP2024516356A (ja) ケトヘキソキナーゼ(khk)を阻害するための組成物及び方法
KR20260064686A (ko) 올리고뉴클레오타이드 조성물 및 이의 방법
Wies Mancini et al. Microglia‐derived extracellular vesicles in homeostasis and demyelination/remyelination processes
JP2023538284A (ja) Plp1発現を阻害するための組成物及び方法
EP4453212A1 (en) Therapeutic treatment for fragile x-associated disorder
Khodabakhsh et al. MicroRNA‐140‐5p inhibitor attenuates memory impairment induced by amyloid‐ß oligomer in vivo possibly through Pin1 regulation
US20240417729A1 (en) Therapeutic treatment for fragile x-associated disorder
US20200368181A1 (en) Methods of treating anti-nmdar-associated neuropsychiatric disorders
WO2025240947A1 (en) Therapeutic treatment for fragile x-associated disorder
HK40111268A (en) Therapeutic treatment for fragile x-associated disorder
WO2019186559A1 (en) Microglia modulators for use in treatment of depression
JP2026504808A (ja) 神経変性疾患の処置のためのポリヌクレオチド組成物および方法
WO2025007066A1 (en) Biomarkers and methods related to fragile x syndrome
KR20240130136A (ko) 근육 세포 표면에서 발현된 단백질을 표적화하는 조직-특이적 영상화제 및 치료제
HK40118713A (en) Methods of using extracellular vesicle-aso targeting stat6